Relapse
104
23
29
30
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.8%
6 terminated out of 104 trials
83.3%
-3.3% vs benchmark
6%
6 trials in Phase 3/4
17%
5 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 30 completed trials
Clinical Trials (104)
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse
Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Comparative 3-dimensional Superimposition Analysis of Dentition in Horizontal and Vertical Grower During the Retention Phase -A Prospective Clinical Trial''
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Study of the Impact on the Evolution of the Disease in the Medium Term of the Implementation of a System of Extended Follow-up by Telephone Interview of Patients With an Eating Disorder Organized by the Nurses of the Eating Disorder Referral Center
Adapted RPM-08 for Substance Use Disorder in Pakistan
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML